177 related articles for article (PubMed ID: 26738606)
1. Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Charehbili A; van Laarhoven HW; Mooyaart AL; Dekker-Ensink NG; van de Ven S; Janssen LG; Swen JJ; Smit VT; Heijns JB; Kessels LW; van der Straaten T; Böhringer S; Gelderblom H; van der Hoeven JJ; Guchelaar HJ; Pijl H; Kroep JR;
Breast Cancer Res; 2016 Jan; 18(1):3. PubMed ID: 26738606
[TBL] [Abstract][Full Text] [Related]
2. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Wauters CA; Strobbe LJ; Mandigers CM; Bult P; Oyen WJ; van der Graaf WT; van Laarhoven HW
PLoS One; 2015; 10(2):e0117745. PubMed ID: 25680198
[TBL] [Abstract][Full Text] [Related]
4. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
Charehbili A; van de Ven S; Smit VT; Meershoek-Klein Kranenbarg E; Hamdy NA; Putter H; Heijns JB; van Warmerdam LJ; Kessels L; Dercksen M; Pepels MJ; Maartense E; van Laarhoven HW; Vriens B; Wasser MN; van Leeuwen-Stok AE; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR;
Ann Oncol; 2014 May; 25(5):998-1004. PubMed ID: 24585721
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma.
Bhargava R; Beriwal S; McManus K; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):218-25. PubMed ID: 21217522
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor receptor-1 overexpression is associated with poor response of rectal cancers to radiotherapy.
Wu XY; Wu ZF; Cao QH; Chen C; Chen ZW; Xu Z; Li WS; Liu FK; Yao XQ; Li G
World J Gastroenterol; 2014 Nov; 20(43):16268-74. PubMed ID: 25473182
[TBL] [Abstract][Full Text] [Related]
7. Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Janssen LG; Charehbili A; Dijkgraaf EM; Smit VT; Kessels LW; van Bochove A; van Laarhoven HW; Meershoek-Klein Kranenbarg E; van Leeuwen-Stok AE; van de Velde CJ; Putter H; Nortier JW; van der Hoeven JJ; Pijl H; Kroep JR
Breast Cancer Res Treat; 2015 Jan; 149(2):461-6. PubMed ID: 25556355
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).
Charehbili A; Hamdy NA; Smit VT; Kessels L; van Bochove A; van Laarhoven HW; Putter H; Meershoek-Klein Kranenbarg E; van Leeuwen-Stok AE; van der Hoeven JJ; van de Velde CJ; Nortier JW; Kroep JR;
Breast; 2016 Feb; 25():69-74. PubMed ID: 26614548
[TBL] [Abstract][Full Text] [Related]
10. [Relationship of insulin-like growth factor receptor single nucleotide polymorphism (SNP) with platinum-based chemotherapy outcomes in advanced non-small cell lung cancer].
Chen Y; Shao H; Li H; Han L; Zhang X
Zhongguo Fei Ai Za Zhi; 2012 Feb; 15(2):65-71. PubMed ID: 22336232
[TBL] [Abstract][Full Text] [Related]
11. CD24 polymorphisms cannot predict pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer.
Zhou X
Clin Breast Cancer; 2014 Apr; 14(2):e33-40. PubMed ID: 24393851
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
13. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.
Hein A; Lambrechts D; von Minckwitz G; Häberle L; Eidtmann H; Tesch H; Untch M; Hilfrich J; Schem C; Rezai M; Gerber B; Dan Costa S; Blohmer JU; Schwedler K; Kittel K; Fehm T; Kunz G; Beckmann MW; Ekici AB; Hanusch C; Huober J; Liedtke C; Mau C; Moisse M; Müller V; Nekljudova V; Peuteman G; Rack B; Rübner M; Van Brussel T; Wang L; Weinshilboum RM; Loibl S; Fasching PA
Int J Cancer; 2015 Dec; 137(12):2981-8. PubMed ID: 26100253
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
16. Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.
Charehbili A; de Groot S; van der Straaten T; Swen JJ; Pijl H; Gelderblom H; van de Velde CJ; Nortier JW; Guchelaar HJ; Kroep JR
Pharmacogenomics; 2015; 16(11):1267-76. PubMed ID: 26289095
[TBL] [Abstract][Full Text] [Related]
17. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.
Miolo G; Muraro E; Martorelli D; Lombardi D; Scalone S; Spazzapan S; Massarut S; Perin T; Viel E; Comaro E; Talamini R; Bidoli E; Turchet E; Crivellari D; Dolcetti R
BMC Cancer; 2014 Dec; 14():954. PubMed ID: 25512030
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
20. Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX.
Oh SY; Shin A; Kim SG; Hwang JA; Hong SH; Lee YS; Kwon HC
Oncotarget; 2016 May; 7(21):31204-14. PubMed ID: 27144430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
